

## BioBusiness Asia 2009

Company Name	GNI-Shanghai Genomics, Inc.		
Presenter	Ying Luo	Title	CEO
Address	647 Song Tao Road, Bldg. 1, Shanghai, China 201203		
Website	www.gnipharma.com		
No. of employee	65	Year of foundation	8
Company Categories	<input type="checkbox"/> Novel Therapeutics <input type="checkbox"/> Genomics <input type="checkbox"/> Pharmaceuticals <input type="checkbox"/> R&D Service <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other _____		
Paid-in Capital	97 million RMB		
Company Stage	<input type="checkbox"/> Seed <input type="checkbox"/> Start up <input type="checkbox"/> Expansion <input type="checkbox"/> Mezzanine		
Company Overview	An innovative drug developer in China		
Company History	2001: Founding of Shanghai Genomics; 2003: Filed IND of Class I drug F647 for Idiopathic Pulmonary Fibrosis; 2005: Merged with GNI Ltd in Japan; 2007: IPO on Tokyo Stock Exchange (Mothers 2160); 2007: Phase I trial of Class I drug F351 for liver fibrosis started in China; 2008: Phase II trial of F647 achieved positive results; 2008: Epicept and GNI form partnership to develop novel liver drug;		
Main Products/ Service & Niche of Products/ Service	F647: class I drug for Idiopathic Pulmonary Fibrosis at NDA preparation stage in China; F351: class I drug for liver fibrosis in Phase I trial in China; F1013: class I drug for acute liver failure in pre-IND studies in China; C45: class I drug for liver and lung cancer in pre-IND studies in China.		
Market Potentials	F647: 200-600 million RMB in China; F351: 1 – 3 billion RMB in China;		
Company Core Competence or Competitive Advantage	Strong innovative drug development experience; High standard research with multiple scientific publications such as PNAS.		
Partnering Objectives	Co-develop of novel drugs for Asian population.		

